Hengroi Pharma and Brave Heart Bio present data from a 52-week open-label extension of the Phase 2 study of HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy at the American Heart Association Scientific.
Hengroi Pharma and Brave Heart Bio present data from a 52-week open-label extension of the Phase 2 study of HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy at the American Heart Association Scientific.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in